CanSino Biologics Inc. (6185.HK)

HKD 33.5

(-1.33%)

Market Cap (In HKD)

10.2 Billion

Revenue (In HKD)

345.18 Million

Net Income (In HKD)

-1.48 Billion

Avg. Volume

1.68 Million

Currency
HKD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
14.8-36.85
PE
-20.55
EPS
-1.63
Beta Value
0.49
ISIN
CNE100003F01
CUSIP
Y1099N102
CIK
-
Shares
304524320.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Dr. Xuefeng Yu Ph.D.
Employee Count
-
Website
https://www.cansinotech.com
Ipo Date
2019-03-28
Details
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.